CRISPR Therapeutics AG (CRSP) Long-Term Investments (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has 5 years of Long-Term Investments data on file, last reported at $28.4 million in Q3 2025.

• For the quarter ending Q3 2025, Long-Term Investments changed N/A year-over-year to $28.4 million; the trailing twelve-month figure through Sep 2025 stood at $28.4 million (changed N/A YoY), and the FY2023 full-year result was $2.0 million, down 96.23% from the prior year.
• Long-Term Investments grew to $28.4 million in Q3 2025, from $11.2 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $77.1 million in Q3 2022 to a low of $2.0 million in Q4 2023.
• A 4-year average of $23.9 million and a median of $9.8 million in 2022 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments plunged 96.23% in 2023 and surged 128.57% in 2024, its largest moves.
• Tracing CRSP's Long-Term Investments over 4 years: stood at $53.1 million in 2022, then sank by 96.23% to $2.0 million in 2023, then surged by 460.0% to $11.2 million in 2024, then jumped by 153.68% to $28.4 million in 2025.
• Business Quant data shows CRSP's Long-Term Investments at $28.4 million in Q3 2025, $11.2 million in Q2 2024, and $2.0 million in Q4 2023.